“We continue to make strong progress on our cardiac and skeletal muscle programs,” said Kevin Koch, Ph.D., President and Chief Executive Officer of Edgewise. “Based on the strength of clinical and preclinical data to-date, we are treating patients with obstructive and non-obstructive HCM in the 28-day part of CIRRUS-HCM trial. We look forward to sharing important updates on both our CIRRUS-HCM and CANYON Phase 2 programs over the coming months.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EWTX:
- Edgewise Therapeutics call volume above normal and directionally bullish
- Edgewise Therapeutics price target raised to $51 from $48 at Piper Sandler
- Largest borrow rate increases among liquid names
- Edgewise Therapeutics put volume heavy and directionally bearish
- Edgewise Therapeutics price target raised to $42 from $32 at RBC Capital
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
